Lower-intensity CPX-351 plus venetoclax for adults with newly diagnosed AML
Talha Badar, Hematology Oncologist based in Mayo Clinic, Jacksonville, posted on X about recent paper by Geoffrey L. Uy et al., titled “Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy” published on ASH Publications.
Authors: Geoffrey L. Uy, Vinod Pullarkat, Praneeth Baratam, Robert K. Stuart, Roland B. Walter, Eric S. Winer, Qi Wang, Stefan Faderl, Divya Chakravarthy, Diane Menno, Ronald S. Cheung, Tara L. Lin.
“Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy.”
Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023